Dive Brief:
- Endo International is slashing 90 full-time positions under a restructuring aimed at lowering costs and driving greater efficiencies and business alignment, the company said Jan. 26.
- The Irish pharma said its latest restructuring actions mainly will affect corporate functions and branded pharmaceutical R&D operations at its U.S. headquarters in Malvern, Pennsylvania, and in Chestnut Ridge, New York. The latter is home to generics-maker Par Pharmaceutical, acquired by Endo in 2015.
- Endo said it expects cost savings from the initiative, part of which it intends to invest into its core product franchises and n…
Read the full article at: http://www.biopharmadive.com/news/endo-slashes-90-jobs-in-latest-restructuring-effort/435048/